C127I Syngeneic Model Service for Breast Cancer

The C127I syngeneic model service for breast cancer is an immune-competent RIII-strain platform built on the classic C127 murine mammary epithelial lineage — a clonal line derived from a mammary tumor of an RIII mouse — supporting syngeneic mammary-tumor studies, oncogene-cooperation experiments, and transformation-biology workflows in a fully immunocompetent host. Alfa Cytology delivers this model as a complete preclinical capability — covering authenticated C127I expansion and banking, subcutaneous or mammary-fat-pad implantation into RIII hosts, scheduled tumor monitoring, and full mammary histopathology with epithelial-marker immunophenotyping — all configured around each sponsor’s mammary tumorigenesis, oncogene-cooperation, or breast-cancer-biology hypothesis.

Overview of C127I Syngeneic Model for Breast Cancer

C127I belongs to one of the most storied lineages in breast cancer research: the C127 mouse mammary epithelial system, from which this clonal line was derived from a mammary tumor arising in an RIII mouse. Two authoritative descriptions together define its identity. ATCC and ECACC record it as a non-transformed clonal line derived from a mammary tumor of an RIII mouse — with reverse-transcriptase-negative culture supernatant — while Cellosaurus catalogs it within malignant neoplasms of the mouse mammary gland, as a female, RIII-breed, mammary-gland epithelial cell line. This combination — tumor-derived yet non-transformed — is precisely what made C127I historically valuable: the parental C127 cells were the substrate of the landmark oncogene-cooperation experiments of the early 1980s, in which adenovirus E1A and activated ras together transformed primary epithelial cells in culture — work that established the two-hit paradigm of carcinogenesis — and C127I itself became the standard transformation host for sarcoma-virus focus-formation assays and for bovine papillomavirus studies, in which the line supports the episomal replication of BPV DNA plasmids and stable expression from papillomavirus-derived vectors.

Fig 1. (Color online) Laser confocal microscopy confirmed C127I cells in different mitotic phases. (Soon, Thomas Tiong Kwong, et al., 2022)

As a syngeneic platform, C127I offers the RIII inbred background (H-2^q) — an immune-competent host context that differs from the more common C57BL/6 and BALB/c breast models and therefore complements the field’s dominant 4T1, EMT6, and PyMT-derived panels. The cells are adherent, epithelial, aneuploid as reported in commercial characterizations, and carry the physiological peculiarities documented for mammary epithelium of this lineage, including volume-activated ATP-conductive anion channels that render them sensitive to hypotonic stress — a trait exploited in ion-channel pharmacology studies. In vivo, the syngeneic service frames C127I as the RIII-native mammary platform: implanted subcutaneously or into the mammary fat pad of RIII hosts, the line supports mammary-tumor growth and stromal-interaction studies with full histological confirmation, while its celebrated in vitro roles — transformation-host assays, oncogene-cooperation readouts, and papillomavirus-vector expression — run alongside as mechanistic companions. For sponsors, C127I is the RIII-strain answer to a specific set of questions: how mammary epithelial cells cooperate with oncogenes, how sarcoma-virus and papillomavirus biology interfaces with breast tumorigenesis, and how a tumor-derived but non-transformed mammary clone behaves within its fully histocompatible host.

Cell Line Information: C127I

The table below consolidates the key biological, cultural, and modeling characteristics of the C127I line, with its documented identity stated plainly.

Our Services

A line whose value is its documented identity rewards exactly the candor Alfa Cytology brings: provenance-authenticated C127I banking with its non-transformed clonal character recorded, RIII syngeneic implantation with scheduled monitoring, and endpoint mammary histopathology with epithelial-marker immunophenotyping — all under one accountable preclinical operation, with the line’s classical transformation-host assays available as companion mechanistic readouts.

Workflow of C127I Syngeneic Model Construction

Construction follows standard syngeneic mammary methodology adapted to the RIII strain: C127I cells are expanded under authenticated conditions, implanted into RIII hosts, monitored, treated, and analyzed with mammary-appropriate endpoints, while companion transformation-host assays run in vitro in parallel. The workflow comprises the following stages.

1. Cell authentication and banking: C127I cells are identity-verified by STR profiling against the C127 lineage reference, confirmed mycoplasma-negative with reverse-transcriptase status documented, and expanded into low-passage working banks under the validated DMEM formulation.
2. Cell harvest and formulation: Sub-confluent cultures are trypsinized, washed, counted and viability-checked, then resuspended at the study-specified dose in PBS or a Matrigel-supported suspension per validated RIII protocol.
3. Anesthesia and implantation: RIII mice are anesthetized with isoflurane; cells are implanted subcutaneously into the flank or injected into the cleared mammary fat pad through a small abdominal or skin approach.
4. Establishment monitoring and randomization: Tumors are measured by caliper from first palpability on a scheduled cadence; animals are randomized once tumors reach protocol-specified baselines, balancing groups by body weight and tumor volume.
5. Treatment administration: Experimental arms — hormonal, targeted, and cytotoxic agents, viral-oncogenesis regimens, and ion-channel-modulating compounds — proceed per study design with body-weight and toxicity monitoring.
6. Companion in vitro transformation assays: Parallel in vitro arms run sarcoma-virus focus-formation, BPV-plasmid replication, and oncogene-cooperation readouts on study cell banks, connecting in vivo outcomes to the line’s classical transformation biology.
7. Endpoint and histopathological analysis: Endpoints integrate tumor-growth kinetics with terminal histopathology (H&E confirming mammary epithelial tumor morphology, plus pan-cytokeratin, E-cadherin, Ki67, CD8, and marker-specific immunohistochemistry) and resected-tumor explant culture for mechanistic follow-up.

Fig 2. C127I Syngeneic Model construction workflow.

Case Study-C127I Syngeneic Model Development

Alfa Cytology has conducted preclinical programs on the C127I platform spanning mammary-tumor growth evaluation in RIII syngeneic hosts, oncogene-cooperation and transformation-host companion assays, and epithelial-biology endpoint characterization. In these studies, implanted C127I tumors were monitored through scheduled caliper measurement, treated per randomized regimens, and characterized at endpoint by mammary histopathology with epithelial-marker immunophenotyping. Study-level datasets are available upon request.

Why Choose Alfa Cytology?

Alfa Cytology pairs lineage-stewardship discipline with RIII-strain operational experience, so every C127I study is executed with provenance-authenticated material, documented identity recorded, and companion transformation assays available as mechanistic anchors.

• Focused experience with the C127 murine mammary lineage, including its non-transformed clonal character and transformation-host heritage.
• A single coordinated team managing cell banking, RIII implantation, companion in vitro assays, and endpoint pathology under one quality framework.
• Provenance and STR authentication at banking protecting the line’s documented identity.
• Endpoint panels pairing mammary histology with pan-cytokeratin, E-cadherin, and Ki67 immunohistochemistry.
• Transparent milestone reporting and rapid scientific feedback throughout the engagement.

Contact Us

If your breast cancer program needs the RIII-strain mammary platform — with its transformation-cooperation heritage and documented identity — Alfa Cytology is ready to build the study around your hypothesis. Reach out to us with your regimen and endpoint requirements, or contact us today for a customized proposal and quotation for the C127I syngeneic model service.

For research use only. Not intended for any clinical use.